Cantor Fitzgerald L. P. Makes New Investment in Insmed Incorporated (NASDAQ:INSM)

Cantor Fitzgerald L. P. bought a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,000 shares of the biopharmaceutical company's stock, valued at approximately $682,000.

Several other institutional investors and hedge funds have also modified their holdings of INSM. Vanguard Group Inc. boosted its holdings in Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares during the period. Darwin Global Management Ltd. boosted its stake in shares of Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after buying an additional 2,463,261 shares during the period. Price T Rowe Associates Inc. MD grew its position in Insmed by 1.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company's stock worth $877,113,000 after buying an additional 123,429 shares in the last quarter. Capital International Investors grew its position in Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock worth $491,357,000 after buying an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock valued at $282,243,000 after acquiring an additional 273,759 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Morgan Stanley raised their target price on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. upped their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. UBS Group boosted their price objective on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, Wells Fargo & Company lifted their price target on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insmed Trading Up 0.6 %

NASDAQ INSM traded up $0.41 on Wednesday, hitting $68.28. The company's stock had a trading volume of 1,875,367 shares, compared to its average volume of 2,318,244. The firm has a market cap of $12.41 billion, a PE ratio of -12.21 and a beta of 0.84. The company's 50-day moving average is $72.82 and its 200 day moving average is $73.37. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. As a group, analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Martina M.D. Flammer sold 33,055 shares of the business's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the transaction, the insider now directly owns 138,053 shares of the company's stock, valued at $11,168,487.70. The trade was a 19.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 6,830 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $72.57, for a total value of $495,653.10. Following the sale, the chief executive officer now owns 233,924 shares in the company, valued at approximately $16,975,864.68. The trade was a 2.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 368,737 shares of company stock valued at $29,364,317 over the last ninety days. 3.00% of the stock is owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.